Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Ovarian Cancer treatment details. Biologic therapy. Chemotherapy. M.D. Anderson Cancer Center, Houston, TX, United States



Survival: 14.0 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Houston, TX
   
Hospital: M.D. Anderson Cancer Center
   
Journal: Link
   
Date: 6/2014

Description:
Patients:
This phase 2 study involved previously treated, persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma patients who were divided into two separate treatment groups. Group A consisted of 66 patients with a median age of 61.7 years. Group B had 63 patients with a median age of 61.9 years.

Treatment:
Patients in group A received chemotherapy with docetaxel.

Patients in group B were treated with the chemotherapy agent docetaxel and the biologic therapy agent vandetanib, a kinase inhibitor that interferes with tumor growth.

Toxicities:
The most severe toxicities in group A were grade 4 and included leukocytosis (increased white blood cell count) and neutropenia.

There was one treatment-related death in group B due to myelosuppression (decreased blood cell count). Grade 4 neutropenia and grade 3 fatigue and rash were also reported.

Results:
The median overall survival rates for groups A and B were 18 and 14 months, respectively.

Support:
This study was partially supported by AstraZeneca, makers of vandetanib.

Correspondence: Dr. Robert L. Coleman; email: rcoleman@mdanderson.org

E-mail to a Friend Email Physician More Information